26 results about "Cholesterol lowering" patented technology

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

The present application provides a kind of compound with indazole group, THR beta receptor agonist and use, compound with indazole group or its pharmaceutically acceptable salt.The present application develops a kind of THR beta selective agonist with better specificity and drugability, the present agonist is better selective agonist THR beta and avoids the activation of THR alpha, separates the harmful influence of thyroid hormone excess from potential beneficial effects such as lowering cholesterol and blood lipids, provides a kind of new type of treatment drug with broad prospects for treating a series of major metabolic diseases in urgent need of solution.

The invention belongs to the technical field of microorganisms, and discloses a new application of ackermania martensii and a new strain Amass-2. The strain is safe, has no toxic factors, and has the functions of reducing cholesterol, inhibiting fat synthesis and reducing body weight.

The invention belongs to the technical field of edible oil, and particularly relates to edible oil with a blood fat reducing effect and a preparation method of the edible oil. Comprising the following raw materials in parts by weight: 1 to 10 parts of base oil, 90 to 100 parts of 1-oleic acid-2-palmitic acid-3-linoleic acid triglyceride, 0.3 to 0.5 part of an emulsifier, 0.05 to 0.09 part of an antioxidant and 0.02 to 0.05 part of a stabilizer. The base oil is composed of the sunflower seed oil and the tea seed oil, and the base oil and the 1-oleic acid-2-palmitic acid-3-linoleic acid triglyceride are matched for use, so that the oil has a good blood fat reducing effect, and can effectively reduce cholesterol, maintain cardiovascular health and prevent arteriosclerosis. The antioxidant is composed of the vitamin E, the alpha-mangostin and the oryzanol, all the components have a synergistic effect and jointly improve the oxidation stability of the edible oil, and meanwhile, the antioxidant is matched with the stabilizer, so that the storage life of the edible oil can be effectively prolonged, and the storage stability is improved.

The invention relates to the technical field of feeds, and particularly discloses a wormwood compound feed capable of reducing cholesterol and resisting viruses as well as a preparation method and application of the wormwood compound feed. The wormwood compound feed comprises the following raw materials: wormwood dry powder, mulberry leaf powder, moringa oleifera leaf powder, a houttuynia cordata extract and a fermentation carrier, the fermentation carrier comprises at least one of lactobacillus fermented soybean meal and lactobacillus fermented corn flour. The invention successfully develops the wormwood compound feed capable of reducing cholesterol and resisting viruses through scientific proportioning and an innovative process. The feed can significantly reduce cholesterol, and has high practical application value and market prospect. Compared with the traditional feed, the feed disclosed by the invention has obvious advantages in the aspects of functionality, safety, bioavailability, economic benefit and the like.

The invention provides a compound with a heterocyclic structure, a THRbeta receptor agonist and application, and the compound with the heterocyclic structure or pharmaceutically acceptable salt thereof. The invention develops a THRbeta selective agonist with better specificity and druggability, the THRbeta selective agonist can better selectively agonize THRbeta so as to avoid activation of THRalpha, and the harmful effect of excessive thyroid hormone is separated from the potential beneficial effects of lowering cholesterol and blood fat and the like; the invention provides a novel therapeutic drug with a wide prospect for treating a series of serious metabolic diseases to be solved urgently.

The present disclosure provides a cholesterol liquid crystal display device and a driving method thereof. The cholesterol liquid crystal display device comprises a cholesterol liquid crystal display panel, a time sequence control module and a driving module. The time sequence control module is used for outputting an enable signal and a latch signal. The driving module is used for receiving the enable signal and the latch signal and outputting a driving voltage to the cholesterol liquid crystal display panel. The enable signal is used for controlling the driving module to stop outputting the driving voltage, and the latch signal is used for controlling the driving module to enable the driving voltage to be discharged to zero volt. Therefore, the power consumption of the cholesterol liquid crystal display device is reduced.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The invention provides application of bacillus natto in fermentation of agrocybe cylindracea and co-production of polypeptide and vitamin K2 and a method, and belongs to the technical field of microbial fermention.The bacillus natto is used for fermentation of agrocybe cylindracea to obtain polypeptide and vitamin K2; the bacillus natto is preserved in Guangdong Microbial Culture Collection Center on October 21, 2020, and the preservation number of the bacillus natto is GDMCC No: 61234. The agrocybe cylindracea polypeptide and the vitamin K2 can be co-produced, compared with a traditional enzyme method for preparing the agrocybe cylindracea peptide, the method has the advantages of being high in conversion rate, simple in process, green, economical and the like, the fermented agrocybe cylindracea peptide has multiple functions of lowering cholesterol and blood sugar and resisting oxidation, and the method has very high application value and economic value.

The present invention relates to a composition for alleviating, preventing, or treating a kidney disease or a vascular disease accompanied by hypoxia, the composition comprising a Panax ginseng extract fermented with a Lactobacillus plantarum strain. When the Lactobacillus palantarum strain is treated with cells, hypoxia-suppressing and cholesterol accumulation-lowering effects are exhibited. Therefore, the composition can be effectively used in a composition for alleviating, preventing, or treating a kidney disease or a vascular disease accompanied by hypoxia.

The present invention describes a cholesterol synthesis inhibitor alone or in association with at least another anticancer agent for use in the treatment of cancers characterized by aberrant expression of hERG1. Further the present invention describes also a kit for a simultaneous, separate or sequential use in the treatment of cancers characterized by aberrant expression of hERG1, said kit comprising a cholesterol lowering agent and at least an anticancer agent, preferably a cholesterol synthesis inhibitor, an anti-hERG1 / β1 integrin complex bispecific antibody and / or chemotherapy agent.

The application provides a preparation method and application of a double-network emulsion gel with anti-freezing property, and belongs to the technical field of food processing. The application takes hydrophilic polysaccharide, plant protein, phytosterol, vegetable fat and water as main raw materials, and adopts a reverse solvent method to prepare an aqueous phase containing plant protein and polysaccharide, so as to form a first layer network structure by using the plant protein and the polysaccharide; then the oil solution of the phytosterol is mixed with the aqueous phase, and a second layer network structure is formed by using the plant protein and the phytosterol in the oil-water mixture; finally, high-speed homogenization is performed to make the double-network structure more compact, and self-assembly is formed during the cooling process to form an emulsion gel; the obtained emulsion gel can resist repeated freezing and thawing, has the health and nutritional characteristics of low saturated fat and reduced cholesterol, and can be widely used to replace animal fat or fat tissue partially or entirely.

The invention belongs to the technical field of microorganisms, and discloses ackermania martensii Amass-1 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: M20241157 and application of the ackermania martensii Amass-1. The strain is safe, has no toxic factors, and has the functions of reducing cholesterol, inhibiting fat synthesis, reducing body weight and improving diarrhea.

The invention discloses lactobacillus mucus fermentation HF04 with cholesterol lowering capacity and application of the lactobacillus mucus fermentation HF04. The lactobacillus mucus fermentation HF04 is lactobacillus mucus fermentation HF04 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.25482. The invention further discloses a preparation method of the lactobacillus mucus fermentation HF04. Probiotic strains with cholesterol removing capacity are screened out according to in-vitro experiments, and strains with good tolerance are obtained through simulated gastric juice and simulated intestinal juice tolerance experiments of the strains. Experiments prove that the lactobacillus mucilaginosus HF04 disclosed by the invention has acid-resistant and cholate-resistant capabilities, and in-vitro and in-vivo experiments show that the lactobacillus mucilaginosus HF04 has cholesterol removal capability; animal experiments show that the strain has the function of remarkably reducing cholesterol, can reduce the level of total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum, and meanwhile, can remarkably reduce the level of liver lipid and relieve liver injury caused by long-term high-fat diet of mice.

The invention relates to the field of probiotic freeze-dried powder, and provides whey protein probiotic freeze-dried powder capable of reducing cholesterol as well as a preparation method and application thereof.Probiotics are lactobacillus paracasei, the lactobacillus paracasei is added into a whey fermentation culture medium to be fermented and centrifugally separated to remove supernate to obtain protein bacterial sludge, xylitol, VC, trehalose and water are added, and the whey protein probiotic freeze-dried powder capable of reducing cholesterol is obtained. And uniformly shearing the mixture, pre-freezing, and carrying out vacuum freeze-drying to obtain the whey protein probiotic freeze-dried powder. The method greatly reduces the production cost, is suitable for large-scale industrial production, and realizes the resource reutilization of whey. The final product is rich in protein nutrition, and can provide abundant nutritional ingredients for the growth of the probiotics, reduce the activity loss of the probiotics and ensure the activity and stability of the probiotics, so that the effects of the probiotics can be kept for a longer time, and a relatively high survival rate can be kept in the transportation and storage processes. The obtained freeze-dried powder can reduce cholesterol and can be used for preparing products for reducing cholesterol.

To provide a dextran having a water-soluble dietary fiber content of a predetermined level or higher.SOLUTION: The present invention provides a branched dextran derived from a lactic acid bacterium belonging to Leuconostoc citreum in which the glycosidic bonds of the branched dextran comprise 50% to less than 99% of α-1, 6 bonds, 1% to less than 40% of α-1,2 bonds, and 0.1 to less than 20% of α-1,3 bonds, the value obtained by dividing the weight average molecular weight of the branched dextran by the number average molecular weight of the branched dextran is 100 to less than 1500, and the branched dextran contains 80% by mass or more of water-soluble dietary fiber.SELECTED DRAWING: None

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention provides a phytosterol-gallic acid derivative with cholesterol lowering and antioxidant activity and a preparation method thereof, and belongs to the technical field of functional food raw material synthesis. A step-by-step construction strategy is adopted, firstly, C-3 site of phytosterol is subjected to succinic acid esterification, then, a flexible bridging unit is further constructed through an ethylene glycol chain segment, finally, gallic acid is introduced into the tail end, and finally, the phytosterol-gallic acid derivative which is also called phytosterol-succinic acid-ethylene glycol-gallic acid is obtained. The designed structure of the derivative avoids the loss of phenolic hydroxyl groups caused by direct esterification, and ensures that trihydroxy groups of gallic acid are kept complete; the adjustability of molecular conformation is effectively improved by introducing an ethylene glycol flexible chain, so that a polyphenol terminal group is easier to expose on an interface, the antioxidant function of the polyphenol terminal group is favorably exerted, meanwhile, the insertion and adaptability of molecules in a biological membrane are improved, and a structural basis is provided for improving the cholesterol lowering potential of sterol.

The invention discloses a preparation method of a low-GI whole grain base material rich in dietary fibers. The method comprises the following steps: step 1, extracting low-GI grain starch; and step 2, enzyme modification of the whole grain base material. According to the invention, 14 whole grain raw materials are screened, and low-GI whole grains are preferably selected and compounded, so that the selection of low-GI food industry raw materials is enriched, and the raw materials are different from single grains in the current market and are multi-grain compound base materials. The whole-grain base material not only meets the low GI requirement, but also is rich in dietary fibers and flavonoid substances, so that the whole-grain base material has the effects of enhancing satiety, promoting intestinal tract movement, regulating gastrointestinal functions, reducing cholesterol and glucose levels, improving vascular elasticity and promoting insulin secretion, and can better meet various requirements in the field of functional foods.

Disclosed are methods of treating a subject in need thereof comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing survival of a subject comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing longevity of treatment with alternating electric field in a subject comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing efficacy of alternating electric fields in a cell comprising applying alternating electric fields, at a frequency for a period of time, to a cell; and contacting one or more cholesterol lowering drugs to the cell, thereby increasing efficacy of the alternating electric fields.

Disclosed are methods of treating a subject in need thereof comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing survival of a subject comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing longevity of treatment with alternating electric field in a subject comprising applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more cholesterol lowering drugs to the subject in need thereof. Disclosed are methods of increasing efficacy of alternating electric fields in a cell comprising applying alternating electric fields, at a frequency for a period of time, to a cell; and contacting one or more cholesterol lowering drugs to the cell, thereby increasing efficacy of the alternating electric fields.

The invention discloses a polypeptide with a function of inhibiting cholesterol esterase activity as well as a preparation method and application thereof, and relates to the technical field of biology. The amino acid sequence of the polypeptide is as shown in any one of SEQ ID NO.1-2. The two kinds of functional polypeptides obtained through screening are derived from natural plant soybeans and have a definite cholesterol lowering effect, the action mechanism of the polypeptides is that the activity of cholesterol esterase is specifically inhibited, hydrolysis and absorption of dietary cholesterol ester are reduced, then the cholesterol level in the body is reduced, and the cholesterol lowering effect is achieved. The action is doubly verified through a molecular docking technology and an in-vitro enzyme activity inhibition experiment, the mechanism is clear, and the action target is definite. In view of the characteristics, the two polypeptides as natural cholesterol-lowering active components can be directly used as functional factors to develop functional food and products in the related medicine field, which are beneficial to maintaining the health level of blood fat (cholesterol), and have remarkable application value and wide market prospect.

3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods of using CA and CA3S to lower lipids and prevent or treat inflammation-associated diseases are also provided.

The invention discloses mink-source lactobacillus plantarum capable of reducing cholesterol and application of the mink-source lactobacillus plantarum, and belongs to the technical field of microorganisms. In order to screen out a strain which is high in cholate tolerance, has a non-BSH-dependent cholesterol lowering mechanism and can be adapted to multiple hosts and is used for replacing a medicine to lower cholesterol, the lactobacillus plantarum ZZM01 is separated from the intestinal tract of a mink, and the lactobacillus plantarum ZZM01 has the advantages that the lactobacillus plantarum ZZM01 can be used for reducing cholesterol; experiments show that the lactobacillus plantarum ZZM01 has broad-spectrum host suitability, a non-BSH-dependent cholesterol lowering mechanism, activity of inhibiting multiple pathogenic bacteria, free radical scavenging capacity and safety, and provides an innovative solution for adjuvant therapy of cross-species hyperlipemia.

The present invention relates to a polyherbal compound based formulation for managing hypertension and related disorders, comprising Dioscin, Withanolide A, Withaferin A, Withanolide D, P-Sitosterol, Diosgenin, Arjunolic Acid, Caffeic Acid, and Kaempferol. The compounds targets multiple mechanistic pathways in hypertension, including the Renin- Angiotensin-Aldosterone System (RAAS), Sympathetic Nervous System, Vascular Resistance, Nitric Oxide, and Stress-Responsive pathways. It offers a comprehensive and synergistic approach for improving vascular health, reducing blood pressure, regulating the levels of HDL and lowering of Cholesterol, LDL and Triglycerides. The compound / s is formulated for enhanced bioavailability and efficacy, and can be used as an adjuvant with antihypertensive agents. The invention also includes methods for extracting, purifying, and standardizing the active ingredients, ensuring consistent quality. The compounds is suitable for managing hypertension, cardiovascular diseases, metabolic disorders, and stress. It can be administered in various dosage forms such as tablets, capsules, syrups, and powders.

The invention provides a compound with an indazole group, a THRbeta receptor agonist and application, and the compound with the indazole group or pharmaceutically acceptable salt thereof. The invention develops a THRbeta selective agonist with better specificity and druggability, the THRbeta selective agonist can better selectively agonize THRbeta so as to avoid activation of THRalpha, and the harmful effect of excessive thyroid hormone is separated from the potential beneficial effects of lowering cholesterol and blood fat and the like; the invention provides a novel therapeutic drug with a wide prospect for treating a series of serious metabolic diseases to be solved urgently.